Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

/p>

3 months to September 9 months to September 30, 30, 2011 2010 2011 2010 $M $M $M $M Net cash provided by operating activities 178.7 142.0 664.2 612.0 Capital expenditure (1) (40.9) (53.5) (135.9) (139.7) Non GAAP free cash flow 137.8 88.5 528.3 472.3

(1) Capital expenditure for the nine months ended September 30, 2010 excludes capital expenditure relating to the acquisition of Lexington Technology Park.

Non GAAP net debt comprises:

September 30, December 31, 2011 2010 $M $M Cash and cash equivalents 276.4 550.6 Restricted cash 21.0 26.8 Convertible bonds (1,100.0) (1,100.0) Building finance obligation (8.3) (8.4) Non GAAP net debt (810.9) (531.0)

NOTES TO EDITORS

THE "SAFEHARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of Shire's Specialty Pharmaceuticals, Human Genetic Therapies and Regenerative Medicines products, as well as the ability to secure new products for commercialization and/or development; government regulation of Shire's products; Shire's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on Shire's products; Shire's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; Shire's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Boston, MA (PRWEB) December 23, 2014 ... presentation, Dr. James L. Sherley, director of the Adult ... attention on an often overlooked and under appreciated unique ... “Asymmetric Self-Renewal by Distributed Stem Cells: Misunderstood in the ... his message to congress participants. He gave the ...
(Date:12/24/2014)... MD (PRWEB) December 23, 2014 ... into law H.R. 83, the Omnibus and Continuing ... first time, made hydrocephalus a condition eligible to ... Programs (CDMRP) administered by the Department of Defense ... with its allies on Capitol Hill, is celebrating ...
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 23, 2014 ... on methyl mercaptan such as its definition, ... also presents product specification, manufacturing process, and ... regions, technology and applications. The analysis also ... survey, marketing channels, industry development trend and ...
(Date:12/24/2014)... The report expects global cell isolation and ... also provides a carefully analyzed data about the vital ... market. , Full Copy of Report @ http://bit.ly/1yUxy0T ... for cell expansion will keep witnessing growth at an ... to be driven by rapid technological advancements, government funding ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... Physical Laboratory (NPL) is working to provide more reliable measurement ... which could lead to much more accurate devices in the ... in 1986. It uses a nano-sized probe to feel the ... Braille on an extremely small scale. The technique can also ...
... SEATTLE, Oct. 20 Adaptive TCR Technologies, a ... the release of its immunoSEQ™ profiling service and ... provide researchers and clinicians the ability to profile ... level of detail that has never before been ...
... ACCESS PHARMACEUTICALS, INC. (OTC Bulletin ... its proprietary drug-delivery platforms to develop treatments in areas ... has submitted additional patent applications, covering its Cobalamin-mediated oral ... drugs, as a result of the growing interest surrounding ...
Cached Biology Technology:Measuring the electrical properties of nano-crystals 2Adaptive TCR Launches the immunoSEQ™ Product Line - Visualizing the Immune System With Next-Generation Sequencing. 2Adaptive TCR Launches the immunoSEQ™ Product Line - Visualizing the Immune System With Next-Generation Sequencing. 3Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology 2Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology 3
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ... robust – with the clinical data to back it ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
(Date:12/10/2014)... 8, 2014 You,ve been here before: you desperately ... remember your password, site key or the answer to your ... grade teacher? Today, Hoyos Labs , ... that will finally put an end to the frustration that ... . 1U leverages a user,s smartphone to acquire his ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... skin. Cancer is not a static disease but during ... defences adapting to new environmental circumstances, protecting against chemotherapy ... Until now little was known about the mechanisms ... is a particularly intriguing way in which a tumour ...
... of carbon in the world,s oceans, which cover 70 ... climate cycles, with many questions remaining unanswered. Between 200 ... "twilight zone" where insufficient sunlight penetrates for microorganisms to ... resident at these depths capture carbon dioxide that they ...
... of spring-run Chinook salmon in California by the end ... at UC Davis, the Stockholm Environment Institute and the ... for managing water resources to protect the salmon runs, ... Thompson, director of the Center for Aquatic Biology and ...
Cached Biology News:Why cancer cells change their appearance? 2Up from the depths: How bacteria capture carbon in the 'twilight zone' 2Warming streams could be the end for salmon 2
... Fixed clamp trays and universal trays ... Magnetic drive Shaking speed: ... 25 mm amplitude Clamps ... 2000 ml, including Fernbach flasks ...
... convenient, and efficient Denatured protein concentration following ... spin column to make handling easy. The ... which were electro-eluted in their Denatured condition. ... high binding capacity fo all pH values. ...
In Western blotting antibodies recognize 94 K protein band, which corresponds to S-layer protein...
High affinity antibodies recognizes HSP70 protein from human cardiac tissue. Could be used for Westerb blotting application, ELISA....
Biology Products: